Auris Medical Stock Price - EARS

Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
$80.29
Small Cap Basic
Monthly Subscription
for only
$33.03
Big Cap Pro
Monthly Subscription
for only
$52.04
VAT not included
Company Name Stock Ticker Symbol Market Type
Auris Medical Holding AG EARS NASDAQ Common Stock
  Price Change Change Percent Stock Price High Price Low Price Open Price Close Price Last Traded
  0.00 0.0% 1.81 0.00 0.00 0.00 1.81 08:59:05
Bid Price Ask Price Spread Spread % News
1.78 1.87 0.09 4.81% - -
Stock Trades Traded Volume Average Volume 52 Week Range
1 85 170,216 1.71 - 22.60
Last Trade Time Type Quantity Stock Price Currency
08:00:02 85 $ 1.81 USD

Auris Medical Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 5.98M 3.30M $ -11.50M -14.64 14.80 3.30M
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Auris Medical News

Loading Messages....

Latest EARS Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical EARS Price Data

Period † Open High Low VWAP Avg. Daily Vol [m] Change %
1 Week2.022.021.711.901298k-0.21-10.40%
1 Month2.9531.712.2872136k-1.14-38.64%
3 Months33.31.712.6539119k-1.19-39.67%
6 Months6.1186.691.713.7130242k-4.308-70.42%
1 Year21.422.61.7110.34301M-19.59-91.54%
3 Years26.461.61.7114.64741M-24.59-93.14%
5 Years95.6159.21.7120.1164800k-93.79-98.11%

Auris Medical Description

Auris Medical Holding Ltd is a clinical-stage biopharmaceutical company. The company develops novel products for the treatment of inner ear disorders. It has two projects in advanced clinical development Keyzilen for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. It is developing Keyzilen for the treatment of acute inner ear (peripheral) tinnitus following traumatic cochlear injury or otitis media (middle ear infection). Keyzilen contains Esketamine hydrochloride, an N-Methyl-D-Aspartate (NMDA) receptor antagonist, formulated in a biocompatible and fully biodegradable gel. It is also developing AM-111 for the treatment of acute inner ear (sensorineural) hearing loss (ASNHL).


Your Recent History
NASDAQ
EARS
Auris Medi..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.